Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024

By sjmartinez • August 7, 2024

Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir J. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093/cid/ciae405. Epub ahead of print. PMID: 39107255.

Tags: COVID-19 severity, COVID-19 vaccine effectiveness, JN.1 and BA.2.86, Publications, Pulmonary, Critical Care & Sleep Medicine, SARS-CoV-2 variants, test-negative design

A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors among a nationally representative sample

Narain K, Markovic D, Escarce JJ. A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik[...]